vipadenant

Vipadenant is a selective, small molecule antagonist of the adenosine A2A receptor (A2AR). It was originally developed by Vernalis and partnered with Biogen Idec for the treatment of Parkinson's disease, where it reached Phase II clinical trials. However, Biogen discontinued its development in 2010 following preclinical toxicology findings. The rights were subsequently licensed to RedoxTherapies and later acquired by Juno Therapeutics (now part of Bristol Myers Squibb via Celgene) for development in immuno-oncology. In the context of cancer, vipadenant is intended to block the immunosuppressive effects of adenosine in the tumor microenvironment, thereby enhancing the anti-tumor activity of T-cell therapies and other immunotherapies.

Other names

vipadenantBIIB-014BIIB014BIIB 014